References
- Braunwald E, Antman EM, Beasley JW et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction – 2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Unstable Angina). Circulation106, 1893–1900 (2002).
- Gibbons RJ, Abrams J, Chatterjee K et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina – summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J. Am. Coll. Cardiol.41, 159–168 (2003).
- Boden WE, O’Rourke RA, Teo KK et al. Optimal medical therapy with or without PCI for stable coronary disease. N. Engl. J. Med.356, 1503–1516 (2007).
- Chaitman BR, Pepine CJ, Parker JO et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA291, 309–316 (2004).
- Chaitman BR, Skettino SL, Parker JO et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J. Am. Coll. Cardiol.43, 1375–1382 (2004).
- Pepine CJ, Wolff AA. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Am. J. Cardiol.84, 46–50 (1999).
- Rousseau MF, Pouleur H, Cocco G, Wolff AA. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am. J. Cardiol.95, 311–316 (2005).
- Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L. Antianginal efficacy of ranolazine when added to treatment with amlodipine: The ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J. Am. Coll. Cardiol.48, 566–575 (2006).
- Morrow DA, Scirica BM, Karwatowska-Prokopczuk E et al. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. Am. Heart J.151, 1186.e1–1186.e9 (2006).
- Morrow DA, Scirica BM, Karwatowska-Prokopczuk E et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA297, 1775–1783 (2007).
- Scirica B, Hedgepeth CM, III, Bode C et al. Ranolazine reduces ischemia as detected on continuous ECG (Holter) in patients with non-ST-elevation ACS in the MERLIN-TIMI 36 Trial. Circulation116 (2007) (Abstract 1799).
- Spertus JA, Jones P, McDonell M, Fan V, Fihn SD. Health status predicts long-term outcome in outpatients with coronary disease. Circulation.106, 43–49 (2002).
- Morrow DA, Scirica BM, Sabatine MS et al. B-type natriuretic peptide and the effect of ranolazine in patients with non-ST elevation acute coronary syndromes in the MERLIN-TIMI 36 trial. Circulation116 (2007) (Abstract 1798).
- Scirica BM, Morrow DA, Hod H et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine For Less Ischemia In Non ST-Elevation Acute Coronary Syndrome Thrombolysis In Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation.116(15), 1647–1652 (2007).
- Hirsch A, Windhausen F, Tijssen JGP, Verheugt FWA, Cornel JH, de Winter RJ. Long-term outcome after an early invasive versus selective invasive treatment strategy in patients with non-ST-elevation acute coronary syndrome and elevated cardiac troponin T (the ICTUS trial): a follow-up study. Lancet369, 827–835 (2007).
- Chaitman BR. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation113, 2462–2472 (2006).
- Cairns JA. Ranolazine: Augmenting the antianginal armamentarium. J. Am. Coll. Cardiol.48, 576–578 (2006).
- Newby LK, Peterson ED. Does ranolazine have a place in the treatment of acute coronary syndromes? JAMA297, 1823–1825 (2007).
Website
- US FDA Dockets management www.fda.gov/ohrms/dockets/ac/03